Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, tolerability, and pharmacokinetics of subcutaneous treprostinil and LY900014 in healthy Japanese subjects
jRCT2080223225Phase 1
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2016
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of treprostinil and insulin lispro in diabetes mellitus type 1 (T1D), type 2 diabetes mellitus (T2DM) and pulmonary arterial hypertension (PAH) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Safety and tolerability of single subcutaneous treprostinil and LY900014 injections and Pharmacokinetics of LY900014 compared with insulin lispro.
02
Drugs
treprostinilinsulin lispro
03
Conditions
diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT2080223225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223225.